Business
BeyondSpring is a clinical-stage global biopharmaceutical company focused on therapies for patients with high unmet medical needs.
BeyondSpring narrowed its FY2025 net loss, but cash burn worsened, equity stayed negative, and insiders sold heavily.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage biopharmaNote
- Lead asset — PlinabulinNote
- Net loss — $1.0M loss, improvedOK
- FCF — -$19.8MWatch
- Equity — -$32.2MWatch
- Insiders — 0 purchases / 51 salesWatch
- Accounting — Forensic screen unavailableNote
Leadership changes
From BeyondSpring Inc.'s own filings, the day they're filed.
- Min Qiu · Chief Executive Officer · appointmenteff. 2026-07-01
- Jiangwen Majeti · appointmenteff. 2026-07-01
- Lan Huang · Chief Executive Officer · departureeff. 2026-07-01
Latest filings
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-13
- 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BeyondSpring Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.